12,424 Shares in CRISPR Therapeutics AG $CRSP Acquired by Bayforest Capital Ltd

Key Points

• Bayforest Capital Ltd has made a new investment of approximately $423,000 in CRISPR Therapeutics AG, acquiring 12,424 shares during the first quarter.
• Institutional investors collectively own 69.20% of CRISPR Therapeutics, with significant stake increases from firms like UBS AM and Millennium Management.
• CRISPR Therapeutics reported a quarterly loss of ($1.29) earnings per share, but beat estimates and had a revenue growth of 72.5% year-over-year.

Bayforest Capital Ltd purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 12,424 shares of the company's stock, valued at approximately $423,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. SFE Investment Counsel lifted its holdings in CRISPR Therapeutics by 5.8% during the first quarter. SFE Investment Counsel now owns 6,507 shares of the company's stock worth $221,000 after acquiring an additional 355 shares in the last quarter. Axxcess Wealth Management LLC lifted its holdings in shares of CRISPR Therapeutics by 4.0% in the first quarter. Axxcess Wealth Management LLC now owns 10,309 shares of the company's stock valued at $351,000 after purchasing an additional 393 shares in the last quarter. GF Fund Management CO. LTD. lifted its holdings in shares of CRISPR Therapeutics by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 2,186 shares of the company's stock valued at $74,000 after purchasing an additional 394 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of CRISPR Therapeutics by 9.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,725 shares of the company's stock valued at $195,000 after purchasing an additional 473 shares in the last quarter. Finally, SVB Wealth LLC bought a new stake in shares of CRISPR Therapeutics in the first quarter valued at about $25,000. 69.20% of the stock is currently owned by institutional investors.

Insider Activity at CRISPR Therapeutics

In other news, Director Simeon George bought 989,812 shares of the firm's stock in a transaction dated Wednesday, July 16th. The shares were bought at an average price of $52.03 per share, with a total value of $51,499,918.36. Following the completion of the transaction, the director owned 1,730,179 shares of the company's stock, valued at $90,021,213.37. This trade represents a 133.69% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.10% of the company's stock.

CRISPR Therapeutics Price Performance

NASDAQ CRSP traded up $0.28 during trading on Monday, reaching $56.54. 1,089,403 shares of the company's stock were exchanged, compared to its average volume of 2,527,549. The business has a 50 day moving average price of $56.73 and a 200-day moving average price of $45.74. The stock has a market capitalization of $5.14 billion, a P/E ratio of -10.38 and a beta of 1.81. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $71.13.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, topping analysts' consensus estimates of ($1.47) by $0.18. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The firm had revenue of $0.89 million for the quarter, compared to the consensus estimate of $6.44 million. During the same quarter in the previous year, the business earned ($1.49) earnings per share. The business's revenue was up 72.5% compared to the same quarter last year. On average, analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CRSP. Bank of America cut their price target on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Needham & Company LLC restated a "buy" rating and issued a $81.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, July 8th. Royal Bank Of Canada boosted their price target on CRISPR Therapeutics from $38.00 to $42.00 and gave the company a "sector perform" rating in a report on Tuesday, August 5th. Piper Sandler reiterated an "overweight" rating and set a $105.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 27th. Finally, Chardan Capital reiterated a "buy" rating and set a $82.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of "Hold" and an average price target of $71.60.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.